155 related articles for article (PubMed ID: 9554278)
1. Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system.
Cryz SJ; Glück R
Dev Biol Stand; 1998; 92():219-23. PubMed ID: 9554278
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs).
Glück R
Vaccine; 1999 Mar; 17(13-14):1782-7. PubMed ID: 10194840
[TBL] [Abstract][Full Text] [Related]
3. Virosomes as carriers for combined vaccines.
Mengiardi B; Berger R; Just M; Glück R
Vaccine; 1995 Oct; 13(14):1306-15. PubMed ID: 8585285
[TBL] [Abstract][Full Text] [Related]
4. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.
Glück R; Mischler R; Brantschen S; Just M; Althaus B; Cryz SJ
J Clin Invest; 1992 Dec; 90(6):2491-5. PubMed ID: 1334977
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice.
Zurbriggen R; Glück R
Vaccine; 1999 Mar; 17(11-12):1301-5. PubMed ID: 10195764
[TBL] [Abstract][Full Text] [Related]
6. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV).
Glück R; Wälti E
Dev Biol (Basel); 2000; 103():189-97. PubMed ID: 11214236
[TBL] [Abstract][Full Text] [Related]
7. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
[TBL] [Abstract][Full Text] [Related]
8. Routine immunization for adults.
Med Lett Drugs Ther; 1990 Jun; 32(819):54-6. PubMed ID: 2140426
[No Abstract] [Full Text] [Related]
9. Comprehensive immunization delivery in conjunction with influenza vaccination.
Grabenstein JD; Smith LJ; Carter DW; Engler RJ; Evans R; Summers RJ
Arch Intern Med; 1986 Jun; 146(6):1189-92. PubMed ID: 3718106
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems.
Glück R; Metcalfe IC
Vaccine; 2003 Jan; 21(7-8):611-5. PubMed ID: 12531327
[TBL] [Abstract][Full Text] [Related]
11. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens.
Glück R
Vaccine; 1992; 10(13):915-9. PubMed ID: 1471412
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
[TBL] [Abstract][Full Text] [Related]
13. [Problems of vaccinations during pregnancy].
Sesti F; Farnè C; Piccione E
Clin Ter; 1988 Apr; 125(1):65-70. PubMed ID: 2974360
[No Abstract] [Full Text] [Related]
14. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults.
McNeil SA; Noya F; Dionne M; Predy G; Meekison W; Ojah C; Ferro S; Mills EL; Langley JM; Halperin SA
Vaccine; 2007 Apr; 25(17):3464-74. PubMed ID: 17270320
[TBL] [Abstract][Full Text] [Related]
15. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G
Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053
[TBL] [Abstract][Full Text] [Related]
16. Influenza virosomes as an efficient system for adjuvanted vaccine delivery.
Glück R; Moser C; Metcalfe IC
Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680
[TBL] [Abstract][Full Text] [Related]
17. The virosome concept for influenza vaccines.
Huckriede A; Bungener L; Stegmann T; Daemen T; Medema J; Palache AM; Wilschut J
Vaccine; 2005 Jul; 23 Suppl 1():S26-38. PubMed ID: 16026906
[TBL] [Abstract][Full Text] [Related]
18. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group.
Parent du Châtelet I; Lang J; Schlumberger M; Vidor E; Soula G; Genet A; Standaert SM; Saliou P
Vaccine; 1997 Mar; 15(4):449-58. PubMed ID: 9141217
[TBL] [Abstract][Full Text] [Related]
19. Vaccinations.
Bentley DW
Clin Geriatr Med; 1992 Nov; 8(4):745-60. PubMed ID: 1423132
[TBL] [Abstract][Full Text] [Related]
20. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
